StreetInsider.com News Articles

Form 424B3 Medicus Pharma Ltd.

Thu, 13 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26915646.html

Form 424B3 Medicus Pharma Ltd.

Thu, 13 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26915646.html

Form 424B3 Medicus Pharma Ltd.

Thu, 13 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26915646.html

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 18:00:00 -0400

Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion

PHILADELPHIA, PA / ACCESS Newswire / August 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today reported financial results for the three and six months ended June 30, 2026, and provided a corporate update highlighting significant regulatory, clinical and strategic achievements across its development portfolio.

During the second

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 18:00:00 -0400

During the second

Form 10-Q Medicus Pharma Ltd. For: Jun 30

Wed, 12 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260812/26914349.html

Form 10-Q Medicus Pharma Ltd. For: Jun 30

Wed, 12 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260812/26914349.html

Form 10-Q Medicus Pharma Ltd. For: Jun 30

Wed, 12 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260812/26914349.html

Medicus Pharma names Dr. Faisal Mehmud CEO of UK unit Antev

Mon, 03 Aug 2026 07:31:08 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, its United Kingdom subsidiary, effective August 30, 2026.

Dr. Mehmud will retain his role as Chief Medical Officer of Medicus and Co-Chairman of Antev's Board of Directors. He succeeds Amit Kohli, who had served as interim CEO of Antev since Medicus completed its acquisition of the company on August 29, 2025. Kohli remained with the company for one year to support the transition of operations, development programs and stakeholder relationships.

Dr. Mehmud holds a medical degree from the University of Cambridge and

Medicus Pharma names Dr. Faisal Mehmud CEO of UK unit Antev

Mon, 03 Aug 2026 07:31:08 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, its United Kingdom subsidiary, effective August 30, 2026.

Dr. Mehmud holds a medical degree from the University of Cambridge and

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Mon, 03 Aug 2026 07:30:00 -0400

Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev

PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, United Kingdom (“Antev”), the Company’s United Kingdom subsidiary, effective August 30, 2026.

Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Mon, 03 Aug 2026 07:30:00 -0400

Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev

Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Mon, 03 Aug 2026 07:30:00 -0400

Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev

Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Mon, 03 Aug 2026 07:30:00 -0400

Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev

Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership

Medicus Pharma gets UAE approval for endometriosis drug study

Fri, 31 Jul 2026 07:30:33 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced that the United Arab Emirates Department of Health – Abu Dhabi has granted investigational new drug authorization for the company's PRECISION-E2 Phase 2a clinical study evaluating Teverelix® in women with moderate-to-severe symptomatic endometriosis.

The authorization follows the department's review of the company's chemistry, manufacturing and controls documentation, along with non-clinical, clinical and safety data. The study may proceed subject to completion of site-specific Institutional Review Board and ethics approvals.

PRECISION-E2 is a prospective, randomized, placebo-controlled study designed to enroll approximately 84 women across multiple sites in the UAE. Participants will be divided equally among four treatment

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Fri, 31 Jul 2026 07:30:00 -0400

Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health

PHILADELPHIA, July 31, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that the United Arab Emirates (UAE) Department of Health – Abu Dhabi ("DOH") has granted Investigational New Drug ("IND") authorization for the Company's PRECISION-E2 Phase 2a clinical study evaluating Teverelix® in women with moderate-to-severe symptomatic endometriosis, a chronic estrogen-dependent inflammatory disease that affects approximately one

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Fri, 31 Jul 2026 07:30:00 -0400

Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Fri, 31 Jul 2026 07:30:00 -0400

Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Fri, 31 Jul 2026 07:30:00 -0400

Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health

Alliance Global Partners Starts Medicus Pharma Ltd. (MDCX) at Buy

Tue, 28 Jul 2026 07:08:00 -0400

Alliance Global Partners analyst Scott Henry initiates coverage on Medicus Pharma Ltd. (NASDAQ: MDCX) with a Buy rating and a price target of $1.00.

For an analyst ratings summary and ratings history on Medicus Pharma Ltd. click here. For more ratings news on Medicus Pharma Ltd. click here.

Shares of Medicus Pharma Ltd. closed at $0.32 yesterday.

Medicus Pharma gets FDA clearance to start Gorlin Syndrome study

Mon, 27 Jul 2026 08:17:53 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced that the U.S. Food and Drug Administration has issued a "Study May Proceed" letter for the company's SKNJCT-005 registrational Phase 2b clinical study evaluating SkinJect® (D-MNA) 200 mcg in patients with Gorlin Syndrome who present with multiple basal cell carcinomas.

The FDA completed its safety review of the company's Investigational New Drug application and issued the letter on July 23, 2026, following Medicus' submission of the SKNJCT-005 protocol and its response to the agency's June 18, 2026, information requests.

The Phase 2b open-label, multicenter study is designed to enroll up to 50 patients and is intended

Medicus Pharma gets FDA clearance to start Gorlin Syndrome study

Mon, 27 Jul 2026 08:17:53 -0400

The Phase 2b open-label, multicenter study is designed to enroll up to 50 patients and is intended

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

Mon, 27 Jul 2026 08:17:00 -0400

SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended patient follow-up

PHILADELPHIA, July 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that the U.S. Food and Drug Administration (“FDA”) has completed its safety review of the Company's Investigational New Drug ("IND") application for SKNJCT-005 and issued a "Study May Proceed" letter authorizing the initiation of the Company's NDA-enabling registrational Phase 2b clinical

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

Mon, 27 Jul 2026 08:17:00 -0400

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

Mon, 27 Jul 2026 08:17:00 -0400